19. Quarterly results of operations (unaudited)

The following is a summary of unaudited quarterly results of operations for fiscal years 2016 and 2015:


	Year 2016
(in millions, except per share data)	First Quarter		Second Quarter			Third Quarter		Fourth Quarter
Net revenue	$	114.9	$	127.9		$	128.0	$	138.1
Gross profit		50.9		58.8			54.9		63.4
Net income (loss)		1.4		(3.0	)		5.0		8.8
Basic net income (loss) per share	$	0.11	$	(0.24	)	$	0.40	$	0.71
Diluted net income (loss) per share	$	0.11	$	(0.24	)	$	0.40	$	0.70


	Year 2015
(in millions, except per share data)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter
Net revenue	$	118.3	$	133.9	$	133.6	$	154.5
Gross profit		52.0		57.5		56.0		64.0
Net income		3.7		9.8		9.1		10.9
Basic net income per share	$	0.29	$	0.79	$	0.73	$	0.88
Diluted net income per share	$	0.29	$	0.78	$	0.72	$	0.86

As discussed in Note 4. Restucturing charges, we recorded restructuring costs of $3.3 million, $3.1 million, $1.8 million, and $1.4 million, in the first quarter, second quarter, third quarter, and fourth quarter of fiscal year 2016, respectively, in association with the 2016 restructuring plan.

As discussed in Note 3. Business combination, during the second quarter of fiscal year 2016, we recorded acquisition related expense of $0.4 million, in association with the Oncura acquisition.

As discussed in Note 11. Commitments, guarantees and contingencies, during the second quarter of fiscal year 2016, we recorded a $10.1 million expenses related to our BK Medical matter.

As discussed in Note 13. Other income (expense), during the second quarter of fiscal year 2016, we recorded a $3.2 million interest charge related to our BK Medical matter.

As discussed in Note 15. Income taxes, during the second quarter of fiscal year 2016, we recognized a $1.5 million increase in uncertain tax positions primarily associated with the BK Medical matter.

As discussed in Note 3. Business combination, during the first quarter of fiscal year 2015, we recorded acquisition related expense of $0.1 million, in association with the Pathfinder acquisition.

As discussed in Note 15. Income taxes, during the third quarter of fiscal year 2015, we recognized a discrete tax benefit of $3.4 million reduction in uncertain tax positions primarily associated with the expiration of statute of limitations.